Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Compass Therapeutics, Inc. on June 15, 2023. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol CMPX. The filing is an emerging growth company report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders, both of which were approved:
- Proposal 1: Election of Directors. Stockholders elected two Class III nominees to serve until the 2026 Annual Meeting:
- Thomas J. Schuetz, MD, PhD: 67,240,784 votes For; 17,368,756 votes Withheld; 12,119,981 Broker Non-votes.
- Richard S. Lindahl, MBA: 84,596,658 votes For; 12,882 votes Withheld; 12,119,981 Broker Non-votes.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the year ending December 31, 2023.
- Votes: 96,574,239 For; 130,740 Against; 24,542 Abstained; 0 Broker Non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the definitive proxy statement on Form DEF 14A filed on April 27, 2023.
Investor Verification Checklist
- Verify the tenure of the newly elected directors (Thomas J. Schuetz and Richard S. Lindahl) through the 2026 Annual Meeting.
- Confirm the engagement of CohnReznick, LLP as the auditor for the fiscal year ending December 31, 2023.
- Review the definitive proxy statement (Form DEF 14A) filed on April 27, 2023, for detailed biographies of directors and background on the auditor ratification.